There are at least nine tau-targeting antibody therapeutics in clinical development for the treatment of Alzheimer’s disease, which makes this therapeutic strategy an interest across many pharmaceutical companies. Here, MAPT is linked to early-onset autosomal dominant Alzheimer disease.